Program launch date: 18th February 2020
A blended education program designed by Springer Healthcare IME, in collaboration with Dr Paul Cornes and Dr Michael Muenzberg, for all medical oncologists, specialist nurses and allied healthcare professionals (HCPs) working with patients for whom biosimilars may represent a treatment option.
Despite their promise, the uptake, and therefore benefits, of biosimilars in oncology has been slower than expected. A key barrier to their uptake is healthcare professional unfamiliarity with the concept of biosimilarity. Despite an increase in medical education, there are several clinical and non-clinical factors that contribute to a lack of confidence among HCPs.
This program aims to provide you with a better understanding of the biosimilar development process and extrapolation of indications concept, and to help improve your confidence in prescribing biosimilars to your patients. Our goal is to focus on the key issues from your point of view in order to support you in resolving and overcoming these barriers.
This expert authored eLearning module focuses on the importance of analytical data during the development process of biosimilars. It also provides a brief overview of the data requirements for approval of these products in Europe.
A range of 6 eLearning modules will focus on various aspects of biosimilars in oncology through a combination of expert video interviews and engaging assessment tools to effectively relay messages and gauge learner knowledge.
The eLearning modules will include the following hot topics:
- Data analytics
- Extrapolation of indications
- Key issues affecting clinician, nurse and patient confidence
- Patient communication
A filmed expert panel discussion. As the use of biosimilars is advanced further in the rheumatology setting, a specialist rheumatologist will share their insights and experiences with leading oncologists to debate the potential issues arising for oncology HCPs in the near future.